Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16887837rdf:typepubmed:Citationlld:pubmed
pubmed-article:16887837lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:16887837lifeskim:mentionsumls-concept:C0750952lld:lifeskim
pubmed-article:16887837lifeskim:mentionsumls-concept:C0013089lld:lifeskim
pubmed-article:16887837lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:16887837lifeskim:mentionsumls-concept:C1519810lld:lifeskim
pubmed-article:16887837lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:16887837pubmed:issue9lld:pubmed
pubmed-article:16887837pubmed:dateCreated2006-10-9lld:pubmed
pubmed-article:16887837pubmed:abstractTextStandard chemotherapy for advanced biliary tract cancer has not been established. The purpose of this study was to evaluate the efficacy and toxicity of a combination chemotherapy of uracil-tegafur (UFT) and doxorubicin in patients with unresectable advanced biliary tract cancer.lld:pubmed
pubmed-article:16887837pubmed:languageenglld:pubmed
pubmed-article:16887837pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16887837pubmed:citationSubsetIMlld:pubmed
pubmed-article:16887837pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16887837pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16887837pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16887837pubmed:statusMEDLINElld:pubmed
pubmed-article:16887837pubmed:monthSeplld:pubmed
pubmed-article:16887837pubmed:issn0368-2811lld:pubmed
pubmed-article:16887837pubmed:authorpubmed-author:IshiiHiroshiHlld:pubmed
pubmed-article:16887837pubmed:authorpubmed-author:FunakoshiAkih...lld:pubmed
pubmed-article:16887837pubmed:authorpubmed-author:MizunoNobumas...lld:pubmed
pubmed-article:16887837pubmed:authorpubmed-author:UenoHidekiHlld:pubmed
pubmed-article:16887837pubmed:authorpubmed-author:OkusakaTakuji...lld:pubmed
pubmed-article:16887837pubmed:authorpubmed-author:IkedaMasafumi...lld:pubmed
pubmed-article:16887837pubmed:authorpubmed-author:YamaoKenjiKlld:pubmed
pubmed-article:16887837pubmed:authorpubmed-author:FuruseJunjiJlld:pubmed
pubmed-article:16887837pubmed:authorpubmed-author:NagaseMichita...lld:pubmed
pubmed-article:16887837pubmed:authorpubmed-author:MorizaneChigu...lld:pubmed
pubmed-article:16887837pubmed:authorpubmed-author:NakachiKoheiKlld:pubmed
pubmed-article:16887837pubmed:authorpubmed-author:HorikawaYukiYlld:pubmed
pubmed-article:16887837pubmed:issnTypePrintlld:pubmed
pubmed-article:16887837pubmed:volume36lld:pubmed
pubmed-article:16887837pubmed:ownerNLMlld:pubmed
pubmed-article:16887837pubmed:authorsCompleteYlld:pubmed
pubmed-article:16887837pubmed:pagination552-6lld:pubmed
pubmed-article:16887837pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:meshHeadingpubmed-meshheading:16887837...lld:pubmed
pubmed-article:16887837pubmed:year2006lld:pubmed
pubmed-article:16887837pubmed:articleTitleEarly phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.lld:pubmed
pubmed-article:16887837pubmed:affiliationNational Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan. jfuruse@east.ncc.go.jplld:pubmed
pubmed-article:16887837pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16887837pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:16887837pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16887837lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16887837lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16887837lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16887837lld:pubmed